Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.
|Videos|July 16, 2020
The Dangers of Respiratory Droplets to Frontline Health Care Providers
Author(s)John Parkinson
A paper examines how these droplets are transmitted and ways to protect these providers from COVID-19.
Advertisement
For health care providers on the front lines of the
Rajiv Dhand, MD, professor and chair, Department of Medicine and associate dean of clinical affairs, University of Tennessee Graduate School of Medicine recently co-authored a paper titled, "
“AGPs such as intubation, bronchoscopy, physiotherapy and suctioning generate potential infectious bioaerosols by provoking coughs and are associated with increased infection rates among employees working in health care," the authors wrote.
In the paper, they describe the various types and sizes of virus-containing droplets present in sneezes and coughs, the locations in the respiratory systems where they deposit, and how certain medical procedures and devices may spread these droplets and the risks for health care professionals.
in the second segment of a two-part interview with Contagion®, Dhand goes in-depth with his findings including what procedures have the highest risks of AGPs and offers some suggestions on the different levels of PPE depending on the procedure.
Advertisement
Related to this article
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.
The antifungal pipeline currently contains 22 agents in the clinical program and many more in the pre-clinical program. Novel products in the clinical program are especially encouraging.
Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Fungal-WHAT? Updates to the WHO Antifungal Pipeline
3
From Pathogen to Infectious Disease Diagnosis: Reflex Testing Targets Hepatitis D Gap
4
Postapproval Surveillance Confirms Ceftobiprole Activity Against MRSA
5